首页> 外文期刊>Seminars in Oncology >Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
【24h】

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

机译:Waldenstrom巨球蛋白血症开始治疗的预后标志物和标准:第二届Waldenstrom巨球蛋白血症国际研讨会共识小组的建议。

获取原文
获取原文并翻译 | 示例
           

摘要

This presentation represents consensus recommendations on prognostic markers and criteria to initiate therapy in patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. The panel recommended that initiation of therapy should not be based on the IgM level per se since this may not correlate with the clinical manifestations of WM. The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss. The presence of progressive, symptomatic lymphadenopathy or splenomegaly provide additional reasons to begin therapy. The presence of anemia with a hemoglobin value of
机译:本演讲代表了与Waldenstrom巨球蛋白血症(WM)患者开始治疗的预后指标和标准的共识性建议,该建议与2002年9月在希腊雅典举行的第二届国际研讨会共同制定。专家组建议不应开始治疗应当基于IgM水平本身,因为这可能与WM的临床表现无关。共识小组一致认为,开始治疗适用于体质症状如反复发烧,盗汗,贫血引起的疲劳或体重减轻的患者。进行性,症状性淋巴结肿大或脾肿大的存在为开始治疗提供了其他原因。由于骨髓浸润而出现血红蛋白值为

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号